Cat Allergy Clinical Trial
Official title:
A Phase II Trial Assessing the Tolerability and Pharmacodynamic Effect of US SLIT Cat Hair in Subject With Cat Allergy and Investigating Efficacy Variables in an Environmental Exposure Chamber Model
Verified date | August 2010 |
Source | ALK-Abelló A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
The main purpose of this trial is to investigate if any of three different doses of cat hair immunotherapy is safe for treatment of cat allergic patients.
Status | Completed |
Enrollment | 60 |
Est. completion date | May 2010 |
Est. primary completion date | March 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - A history of rhinoconjunctivitis on exposure to cats - Positive Skin Prick Test response (wheal diameter at least 3 mm larger than the negative control - Positive specific IgE against Fel d1 (at least IgE Class 2) - Minimum qualifying rhinoconjunctivitis symptom score during EEC exposure at Visit 2 Exclusion Criteria: - Uncontrolled asthma within the past 12 months, or asthma requiring regular use of inhaled corticosteroids - FEV1 less than 80% of predicted - Subjects who suffer from significant seasonal allergic rhinoconjunctivitis, and cannot complete the clinical trial outside the local pollen season, or who have significant allergy to other allergens (e.g. other animals or house dust mites) that cannot be avoided during the trial period - Subjects who cannot tolerate baseline challenge in the Environmental Exposure Chamber - History of anaphylaxis with cardio/respiratory symptoms - A medical history of severe drug or food allergy with symptoms such as difficulty breathing, swelling of the face or a feeling of severe dizziness or increased heart rate - Chronic urticaria - History of severe cardiac disease - Treatment with immunosuppressives, anti-IgE monoclonal antibodies, tricyclic antidepressants or MAOIs |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Cetero Research | Mississauga | Ontario |
Lead Sponsor | Collaborator |
---|---|
ALK-Abelló A/S | Cetero Research, San Antonio |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse Events | During 16 weeks of treatment | Yes | |
Secondary | Rhinoconjunctivitis symptom score | After 0, 8, and 16 weeks of treatment | No | |
Secondary | Overall rhinoconjunctivitis symptom score | After 0, 8, and 16 weeks of treatment | No | |
Secondary | Acoustic Rhinometry | After 0, 8, and 16 weeks of treatment | No | |
Secondary | Environmental Exposure Chamber Quality of Life | After 0, 8, and 16 weeks of treatment | No | |
Secondary | Serum immunology | After 0, 8, and 16 weeks of treatment | No | |
Secondary | Nasal secretion immunology | After 0 and 16 weeks of treatment | No | |
Secondary | Safety lab testing (clinical chemistry, haematology, urinalysis) | After 0 and 16 weeks of treatment | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02959073 -
Evaluation of a New Self-assessed, Home-based Symptom Score in Cat Allergic Patients
|
N/A | |
Completed |
NCT01383603 -
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis
|
Phase 1 | |
Completed |
NCT01383590 -
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis
|
Phase 1 | |
Completed |
NCT01003301 -
The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge
|
Phase 2 | |
Completed |
NCT02311413 -
A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy
|
Phase 2 | |
Completed |
NCT02237196 -
Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy
|
Phase 1/Phase 2 | |
Completed |
NCT02399579 -
Evaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients
|
N/A | |
Terminated |
NCT01292070 -
Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy
|
Phase 0 | |
Completed |
NCT00867906 -
Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma
|
Phase 2 | |
Completed |
NCT04435678 -
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
|
N/A | |
Completed |
NCT01033344 -
Cat-PAD Exposure Chamber Study
|
Phase 2 | |
Completed |
NCT00685711 -
Safety of Cat-PAD in Cat Allergic Subjects
|
Phase 1/Phase 2 | |
Completed |
NCT02040844 -
Phase III Cat-PAD Follow-on Study
|
Phase 3 | |
Completed |
NCT01604018 -
An Optional Two Year Follow Up Study to Study CP005A
|
N/A | |
Completed |
NCT01272323 -
Cat-PAD Follow on Study
|
N/A | |
Completed |
NCT03838731 -
Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge
|
Phase 2 | |
Completed |
NCT00729508 -
Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects
|
Phase 2 | |
Recruiting |
NCT05331170 -
Viral Mucosal Reprogramming
|
Phase 2 |